Can Fite Biopharma Ltd Company Profile (NASDAQ:CANF)

About Can Fite Biopharma Ltd (NASDAQ:CANF)

Can Fite Biopharma Ltd logoCan Fite Biofarma Ltd is an Israel-based biopharmaceutical company. The Company develops new treatments for autoimmune diseases and cancer. The Company's drugs are CF101 for Psoriasis treatment, RA treatment, for the treatment of Keratoconjunctictivitis Sicca, for the treatment of Glaucoma, among others; and CF102 for the treatment of liver diseases. The Company has a research infrastructure including research laboratories and animal house facilities run by the development team. Can Fite Biofarma Ltd signed distribution contracts with a Kwang Dong Pharmaceutical Co. allowing distribution of CF101 for arthritis in Korea and Seikagaku Corp. for distribution in Japan. The Company operates three subsidiaries, Ultratrend Ltd, EyeFite Ltd and OphathaliX Inc.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CANF
  • CUSIP: N/A
  • Web: www.canfite.co.il
Capitalization:
  • Market Cap: $28.69 million
  • Outstanding Shares: 17,363,000
Average Prices:
  • 50 Day Moving Avg: $1.70
  • 200 Day Moving Avg: $1.77
  • 52 Week Range: $1.50 - $2.67
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.37
  • P/E Growth: 0.0000
Sales & Book Value:
  • Annual Revenue: $215,366.00
  • Price / Sales: 133.23
  • Book Value: $0.23 per share
  • Price / Book: 7.18
Profitability:
  • EBITDA: ($9,070,000.00)
Misc:
  • Average Volume: 28,573 shs.
  • Short Ratio: 5.24
 

Frequently Asked Questions for Can Fite Biopharma Ltd (NASDAQ:CANF)

What is Can Fite Biopharma Ltd's stock symbol?

Can Fite Biopharma Ltd trades on the NASDAQ under the ticker symbol "CANF."

Where is Can Fite Biopharma Ltd's stock going? Where will Can Fite Biopharma Ltd's stock price be in 2017?

2 brokers have issued 1 year price objectives for Can Fite Biopharma Ltd's shares. Their predictions range from $6.00 to $7.00. On average, they expect Can Fite Biopharma Ltd's stock price to reach $6.50 in the next twelve months. View Analyst Ratings for Can Fite Biopharma Ltd.

Who are some of Can Fite Biopharma Ltd's key competitors?

How do I buy Can Fite Biopharma Ltd stock?

Shares of Can Fite Biopharma Ltd can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Can Fite Biopharma Ltd's stock price today?

One share of Can Fite Biopharma Ltd stock can currently be purchased for approximately $1.65.


MarketBeat Community Rating for Can Fite Biopharma Ltd (NASDAQ CANF)
Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  25 (Vote Outperform)
Underperform Votes:  21 (Vote Underperform)
Total Votes:  46
MarketBeat's community ratings are surveys of what our community members think about Can Fite Biopharma Ltd and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Can Fite Biopharma Ltd (NASDAQ:CANF) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $6.50 (293.34% upside)
Consensus Price Target History for Can Fite Biopharma Ltd (NASDAQ:CANF)
Price Target History for Can Fite Biopharma Ltd (NASDAQ:CANF)
Analysts' Ratings History for Can Fite Biopharma Ltd (NASDAQ:CANF)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/17/2017Maxim GroupSet Price TargetBuy$7.00N/AView Rating Details
8/10/2017HC WainwrightSet Price TargetBuy$6.00LowView Rating Details
(Data available from 10/18/2015 forward)

Earnings

Earnings History for Can Fite Biopharma Ltd (NASDAQ:CANF)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Can Fite Biopharma Ltd (NASDAQ:CANF)
Current Year EPS Consensus Estimate: $-0.3000 EPS
Next Year EPS Consensus Estimate: $-0.4900 EPS

Dividends

Dividend History for Can Fite Biopharma Ltd (NASDAQ:CANF)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Can Fite Biopharma Ltd (NASDAQ:CANF)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Can Fite Biopharma Ltd (NASDAQ:CANF)
Latest Headlines for Can Fite Biopharma Ltd (NASDAQ:CANF)
Source:
DateHeadline
americanbankingnews.com logoAnalysts Expect Can Fite Biopharma Ltd (CANF) to Post ($0.14) Earnings Per Share
www.americanbankingnews.com - October 17 at 10:42 PM
americanbankingnews.com logoMaxim Group Analysts Give Can Fite Biopharma Ltd (CANF) a $7.00 Price Target
www.americanbankingnews.com - October 17 at 10:56 AM
finance.yahoo.com logoEarnings Review and Free Research Report: Can-Fite’s Revenue Increased 25%
finance.yahoo.com - September 25 at 7:53 PM
americanbankingnews.com logoMateon Therapeutics (MATN) versus Can Fite Biopharma (CANF) Head-To-Head Contrast
www.americanbankingnews.com - September 20 at 8:08 AM
americanbankingnews.com logoMaxim Group Reaffirms Buy Rating for Can Fite Biopharma Ltd (CANF)
www.americanbankingnews.com - September 19 at 2:32 PM
americanbankingnews.com logo Can Fite Biopharma Ltd (CANF) Receives Average Rating of "Strong Buy" from Brokerages
www.americanbankingnews.com - September 16 at 10:38 PM
americanbankingnews.com logoCan Fite Biopharma Ltd (CANF) Receives "Buy" Rating from Maxim Group
www.americanbankingnews.com - September 4 at 2:32 PM
americanbankingnews.com logoCan Fite Biopharma Ltd (NASDAQ:CANF) Earns Buy Rating from Analysts at Maxim Group
www.americanbankingnews.com - August 13 at 4:02 PM
streetinsider.com logoCan-Fite BioPharma (CANF) Receives Notice of Allowance in Europe for Piclidenoson-Related Patent
www.streetinsider.com - September 13 at 8:54 AM
seekingalpha.com logoCan-Fite Biopharma revenues up 33% in 1H16
seekingalpha.com - August 26 at 12:06 PM
streetinsider.com logoCan-Fite BioPharma (CANF) Posts Wider Net Loss in H116
www.streetinsider.com - August 26 at 12:06 PM
baystreet.ca logoCan-Fite Catapults NASH Indication Into Phase II Aiming for $35 Billion Market
www.baystreet.ca - July 28 at 12:49 PM
benzinga.com logoMid-Morning Market Update: Markets Open Lower; Tesla's Deliveries Hit Near 2-Year Low
www.benzinga.com - July 5 at 4:01 PM
seekingalpha.com logoCan-Fite Bio's lead product candidate flunks mid-stage glaucoma study; shares down 23% premarket
seekingalpha.com - July 5 at 4:01 PM
streetinsider.com logoCan-Fite BioPharma (CANF) Announces New Data Showing CF101 May Offer Efficacy Similar to Leading Biologics Without Harmful Side Effects
www.streetinsider.com - June 15 at 4:08 PM
seekingalpha.com logoCan-Fite finalizes design of late-stage study of CF101 in rheumatoid arthritis, enrollment to start no later than Q3
seekingalpha.com - June 3 at 8:20 AM
streetinsider.com logoCan-Fite BioPharma (CANF) Will Present CF602 Data at AUA 2016 - StreetInsider.com
www.streetinsider.com - May 2 at 9:17 AM
streetinsider.com logoCan-Fite BioPharma (CANF) Announces Positive New Pre-Clinical Data for CF602 - StreetInsider.com
www.streetinsider.com - April 12 at 1:03 PM
streetinsider.com logoForm 6-K Can-Fite BioPharma Ltd. For: Apr 01 - StreetInsider.com
www.streetinsider.com - April 1 at 3:00 PM
streetinsider.com logoCan-Fite BioPharma (CANF) Submits EMA Protocol Design for Phase III Trial of Lead Compound CF101 - StreetInsider.com
www.streetinsider.com - March 18 at 2:19 PM
nytimes.com logoTranscript of the Republican Presidential Debate in Florida - New York Times
www.nytimes.com - March 12 at 1:41 PM
cnn.com logoTranscript of Republican debate in Miami, full text - CNN International
www.cnn.com - March 12 at 1:41 PM
investorplace.com logoHottest Manufacturing Stocks Now - CRMD TUMI JOY TSE - Investorplace.com
investorplace.com - March 3 at 2:53 PM
prnewswire.com logoCan-Fite to Present Psoriasis Data at American Academy of Dermatology's 74th Annual Meeting in Washington D.C. on ... - PR Newswire (press release)
www.prnewswire.com - March 3 at 2:53 PM
bloomberg.com logoVodafone Unit Scraps Neotel Deal After Two-Year Regulatory Fight - Bloomberg
www.bloomberg.com - March 2 at 2:47 PM

Social

Chart

Can Fite Biopharma Ltd (CANF) Chart for Wednesday, October, 18, 2017

This page was last updated on 10/18/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.